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Abstract
Hendra virus (HeV) and Nipah virus (NiV) are closely related paramyxoviruses that infect and cause disease in a wide range of mammalian hosts.
To determine whether host receptor molecules play a role in species-specific and/or virus-specific infection we have cloned and characterized ephrin-
B2 and ephrin-B3 ligands from a range of species, including human, horse, pig, cat, dog, bats (Pteropus alecto and Pteropus vampyrus) and mouse.
HeV and NiV were both able to infect cells expressing any of the ephrin-B2 and ephrin-B3 molecules. There did not appear to be significant
differences in receptor function from different species or receptor usage by HeV and NiV. Soluble ephrin ligands, their receptors and G-specific
human monoclonal antibodies differentially blocked henipavirus infections suggesting different receptor affinities, overlapping receptor binding
domains of the henipavirus attachment glycoprotein (G) and that the functional domains of the ephrin ligands may be important for henipavirus binding.
© 2007 Elsevier Inc. All rights reserved.Keywords: Henipavirus; Ephrin-B2; Ephrin-B3; Multi-species tropism; Ephrin receptors; TherapeuticsIntroduction
Hendra virus (HeV) and Nipah virus (NiV) are closely
related, highly pathogenic paramyxoviruses that have indepen-
dently emerged in the past 15 years and continue to re-emerge in
new locations. Flying foxes in the genus Pteropus are con-
sidered to be the natural reservoir for both viruses and indeed
their geographic range encompasses all locations where HeV
and NiV have emerged (Chua et al., 2002; Halpin et al., 2000).
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doi:10.1016/j.virol.2007.11.011humans (reviewed in Eaton et al., 2006). Most fatalities
have occurred in horses where disease presented as a severe
respiratory infection. To date, there have been two human
mortalities; one presented with severe respiratory disease and
another died of encephalitis 13 months post-exposure. Recent
outbreaks of HeV where horse fatalities have been documented
include 1999, 2004, 2006 and 2007 and one mildly ill,
seroconverting, human case was reported in 2004 (Anonymous,
2006, 2007; Hanna et al., 2006; Westbury, 2000). NiV first
appeared in Malaysia and Singapore in 1998–1999 and the
majority of infections first occurred in pigs and were then
transmitted to humans (reviewed in Chua, 2003; Tan and Wong,
2003). In pigs, infection manifested primarily as a respiratory
disease with some encephalitis but with a relatively low mor-
tality rate whereas in humans, it manifested as a severe febrile
encephalitis with high case fatality (Chua, 2003). Additionally,
up to 25% of cases exhibited respiratory signs and a significant
number of patients experienced delayed relapsed encephalitis
with a significant fatality rate (∼18%). Dogs in close proximity
to infected pigs demonstrated a high seroprevalence to NiV and
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demonstrated respiratory disease and abnormalities in the brain
(Hooper et al., 2001). Clinical features of NiV infected cats
resembled those seen in humans and pigs, particularly with
respect to tropism for endothelial cells and the respiratory epi-
thelium (Hooper et al., 2001; Middleton et al., 2002). Cats have
been used in experimental infection models with both HeV and
NiV (Mungall et al., 2006; Williamson et al., 1998) and like
HeV-infected horses, HeV- and NiV-infected cats exhibit severe
respiratory disease and a high mortality rate but encephalitis has
not been identified although virus does enter the central nervous
system (CNS).
Paramyxoviruses are large, enveloped, negative-sense single
stranded RNA viruses that generally have a narrow host range
(Yin et al., 2006). HeV and NiV have been classified into the
new Henipavirus genus of the family Paramyxoviridae, and are
unique in that they exhibit a broad species tropism and cause
fatal disease in both animals and humans (Eaton et al., 2006,
2005; Hooper et al., 2001). Paramyxoviruses contain two major
membrane-anchored envelope glycoproteins that are required
for infection of a receptive host cell. All members contain a
fusion (F) glycoprotein which mediates pH-independent mem-
brane fusion between the virus and its host cell, while the
second is the attachment glycoprotein which binds the host cell
receptor (reviewed in Yin et al., 2006). HeV and NiV possess
attachment glycoproteins that lack hemagglutinin and neurami-
nidase activities and are designated G for glycoprotein (reviewed
in (Bossart and Broder, in press)). Other than morbilliviruses,
henipaviruses are the only other paramyxoviruses characterized
to date known to utilize host cell proteins as receptors. Recently,
ephrin-B2 ligand (EFNB2) was identified as a receptor em-
ployed by HeV and NiV for infection (Bonaparte et al., 2005;
Negrete et al., 2005) and shortly thereafter, ephrin-B3 ligand
(EFNB3) was identified as a receptor for NiV (Negrete et al.,
2006). Ephrin molecules are highly conserved across vertebrate
species and are members of a family of receptor tyrosine kinase
ligands (Drescher, 2002; Poliakov et al., 2004). The ephrin-B
ligands contain transmembrane and cytoplasmic domains and
participate in bi-directional signaling events upon receptor
binding; forward signaling into an ephrin receptor (Eph) bearing
cell and reverse signaling where they signal into the cell upon
which they are expressed (Palmer and Klein, 2003). Human
EFNB2 and EFNB3 share 39% amino acid identity. The high
level of conservation of these receptors across many species has
helped explain why HeV and NiV, unlike other paramyx-
oviruses, are capable of such a broad species tropism. EFNB2 is
highly expressed on neurons, smooth muscle, arterial endothe-
lial cells and capillaries; closely paralleling the known tissue
tropism of HeVand NiV in vivo. EFNB3 is expressed in specific
regions of the central nervous system (CNS) and may facilitate
pathogenesis in certain neural subsets.
The underlying host and viral factors influencing the patho-
genicity of HeVand NiV in different species is largely unknown.
To begin to understand receptor molecule function across various
susceptible animal species, we cloned and characterized EFNB2
and EFNB3 from human, horse, pig, cat, dog, mouse and two
flying foxes, Pteropus alecto, and Pteropus vampyrus. HeVandNiV were capable of infecting cells expressing any and all of the
various species of EFNB2 and EFNB3. Importantly, there did not
appear to be differences in receptor function from different
species or receptor usage by HeVand NiV. Soluble EFNB2 and
G-specific human monoclonal antibodies (hmAbs) blocked
henipavirus infection mediated by either ephrin from all species,
suggesting all EFNB2 and EFNB3 molecules bind an over-
lapping domain of the henipavirus attachment glycoprotein (G).
Ephrin receptors EphB3 and EphB4 inhibited HeV and NiV
infections significantly suggesting that the Eph binding domain
of the ephrin ligands may be important for binding the henipa-
virus G glycoprotein. Our results demonstrate that both EFNB2
and EFNB3 molecules from a variety of animals can function as
highly efficient receptors for both NiV and HeV. These findings
may have important implications for our understanding of the
epidemiology and pathogenesis of these viruses as well as for the
development of novel therapeutics.
Results
Selection and cloning of ephrin ligands
In order to assess whether ephrin ligands played a role in the
observed differential henipavirus disease manifestations, we
chose to clone and characterize the EFNB2 and EFNB3 mole-
cules from a variety of alternative species known to be naturally
or experimentally susceptible to infection. Specifically we in-
cluded human, horse, pig, cat, dog, mouse and the flying foxes
P. alecto and P. vampyrus. Human, horse, pig, cat and dog all
exhibited different clinical symptoms and mortality rates during
the HeV and NiV outbreaks. P. alecto and P. vampyrus were
chosen as they are the natural reservoir for HeV and NiV but
only develop subclinical disease upon infection (Middleton
et al., 2007). NiV and HeV do not cause disease in mice after
subcutaneous administration (Crameri, G and Eaton, B.T., un-
published observations) or with either an intranasal or intra-
peritoneal challenge of NiV (Wong et al., 2003), although they
are lethal if administered intracranially. The absence of systemic
henipavirus disease in mice is unique and differences in EFN
molecules could account for such differences as EFNB2 is
widely expressed, whereas EFNB3 expression is restricted to
the CNS. To ensure no cell culture adapted mutations existed;
fresh kidney and liver tissues were obtained for all species
with the exception of human, where cDNA clones were already
available (Bonaparte et al., 2005). We found that liver con-
sistently gave good yields of high quality RNA and was thus
used for most EFN cloning except for the cloning of EFNB3
from P. alecto where brain tissue was used. For horse, cat,
P. alecto and P. vampyrus no sequence data were available for
EFNB2 and/or EFNB3 molecules. By using a combination of
RT-PCR and 5′ and 3′ RACE strategies as detailed in Materials
and methods, we were able to generate full-length cDNA clones
from each species. For the pig, dog and mouse, specific primers
were designed based on published sequence data and the full-
length EFNB2 and EFNB3 open reading frames were amplified
from cDNA. For human, specific primers were used to amplify
both ephrin ligands from pre-existing DNA constructs. For each
Table 2
DNA and amino acid sequence identities of ephrin ligands
EFNB2 EFNB3
DNA Amino acid DNA Amino acid
Human 100 100 100 100
Horse 95 96 95 98
Pig 95 96 95 97
Cat 94 96 93 97
Dog 93 96 95 97
P. alecto 94 95 94 97
P. vampyrus 94 95 94 97
Mouse 91 96 91 95
All sequences were aligned to human reference sequence using Clone Manager
Professional Suite version 8 software. For DNA sequences global-reference
alignments were done using a standard linear scoring matrix. For amino acid
sequences global alignments were done using a standard linear scoring matrix.
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sequencing and characterization (Table 1).
Analysis of EFNB2 and EFNB3 DNA and protein sequences
The EFNB2 DNA sequences were aligned to one another
and percent identities are shown in Table 2. There was a high level
of conservation among all species, ranging from 93 to 95%, with
the exception of mouse whose identity was slightly lower, 91%.
Similar results were obtained when all EFNB3 DNA sequences
were aligned to one another. Here the percent identity ranged from
91 to 95% and again mouse demonstrated the lowest level of
conservation (Table 2). Because we were interested in the
function of EFNB2 and EFNB3 molecules as viral receptors we
next aligned the putative amino acids (aa) sequences of EFNB2
and EFNB3 molecules and results are shown in Figs. 1 and 2,
respectively. As was seen with the DNA alignments, the EFNB2
proteins had significant percent identities ranging from 95 to 96%
(Table 2). Althoughmost aa changeswere single substitutions, we
identified a small region (residues 182–187) in both bat se-
quences that appeared to be significantly different. These aa
changes were not present in any other species and could have
represented changes in EFNB2 that decreased henipavirus
receptor function. The EFNB3 molecules also had high sequence
identities, ranging from 95 to 98% (Table 2). Like EFNB2, most
substitutions were single aa changes; however, aa 21 and 22
varied in different species and the region between residues 200
and 208 had several changes. Bat and mouse were different from
all other species in these regions and like EFNB2, these changes
could affect henipavirus receptor function.
Expression of ephrin ligands
To discern whether the aa sequence differences had an effect
on receptor function we established a transient expressionTable 1
Primers used for PCR amplification of EFN molecules
EFNB2 primers
Internal
Forward CTACCTGGACAAGGACTGG
Reverse GGATGATAATGTCACTGGG
RACE
5′ RACE outer CTTTATAATATTCATACTGGCCAACAG
5′ RACE inner GAGTCCACTTTGGGGCAAATAATATCC
3′ RACE outer AGCACACGGCCACGCTGTCAC
3′ RACE inner AGCACGCTGGCCACGCCCAAGC
Cloning
Consensus Forward GTCGACCACCATGGCYGYGAGRAGGGA
Consensus Reverse GTCGACTCTCAGACCTTRTAGTAAATGT
Mouse Forward GTCGACCACCATGGCCATGGCCCGGTCC
Mouse Reverse GTCGACGGCCTCAGACCTTGTAGTAAAT
Dog Forward a GTCGACCACCATGGCCGCGAGGAG
Dog Reverse a GTCGACTCAGACCTTGTAGTAAATG
Cat-pig Forward
Cat-pig Reverse
a The same primers were used for dog and pig EFNB2.system in HeLa-USU cells, a cell line previously shown to be
non-permissive for HeV and NiV (Bonaparte et al., 2005). All
ephrin expression constructs were transfected overnight using
equal amounts of DNA and a liposomal transfection reagent as
described in Materials and methods. As the functional domains
of EFNB2 and EFNB3 molecules were likely to be highly
conserved in all species we speculated that the ephrin receptor
(Eph) molecules, EphB3 and EphB4 could be used for EFN cell
surface staining in all species. Live cells were used for immu-
nofluorescence, and results for EFNB2 and EFNB3 expression
are shown in Figs. 3 and 4, respectively. EphB3 bound all
EFNB2 molecules similarly and verified cell surface expression
of these proteins from all species. EphB3 also bound all EFNB3
molecules similarly and provided evidence of cell surface
expression from all species. EphB4 bound all EFNB2molecules
similarly but was unable to bind EFNB3 (data not shown). To
further examine differential Eph-EFN binding, recombinant
EFN and Eph molecules were used for binding and competition
assays. To increase assay sensitivity, multiplexed microsphereEFNB3 primers
CAGCCTGGAGCCTGTCTACTG
GCCCATCCTGCACGATRTACAC
GCTGGCGCTGCTCTTGCTGG
GTGACCCCACCAGCAATGCAA
GCTGGCGCTGCTCTTGCTGG
CACCCTGGTCCTGGCTCCTT
CTCC GTCGACCACCATGGGGCCCCCCCATTCTGG
TC GTCGACGAGRAGCCCTCATACCTTGTAG
AGGAG GTCGACCACCATGGGGGCCCCCCATTTTGG
GTTG GTCGACGAGGAGCCCTCATACCTTGTAATAG
GTCGACCACCATGGGGGCCCTGCGTTC
GTCGACTCACCGGGACGGCCG
GTCGACCACCATGGGGGCCCCSCGTTCTG
GTCGACGGAGRAGCCCTCATACCTTGTAG
Fig. 1. Amino acid sequence alignment of EFNB2 from different species. Species and amino acid number are listed on the left and right, respectively. Dots represent
identical amino acids; hyphens represent gaps introduced to maximize sequence alignments. The transmembrane domain is indicated by boxed borders, cysteine
residues are shaded in gray, and putative glycosylation sites are underlined. GenBank accession numbers: horse EFNB2:EF682140; pig EFNB2:EF682141; cat
EFNB2:EF682138; dog EFNB2:EF682139; P. alecto EFNB2:EF682142; P. vampyrus EFNB2:EF682143; mouse EFNB2:NM_010111.
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as described in Materials and methods. Briefly, EFN molecules
were coupled to spectrally distinct fluorescently labeled micro-
sphere subsets and Eph molecules were biotinylated. Binding of
biotinylated Eph molecules to each EFN-coupled microsphere
subset was quantified in the absence and presence of non-
biotinylated Eph molecules and median fluorescent intensities
(M.F.I) are shown in Fig. 5. Consistent with the immunofluor-
escence data, EphB3 bound EFNB2 and EFNB3 (Fig. 5A).
Non-biotinylated EphB4 did not block EphB3 binding to either
EFN molecule, non-biotinylated EphB3 was included as a
control and completely blocked binding to both EFNmolecules.
EphB4 bound EFNB2 as expected (Fig. 5B); however, M.F.I.
values were significantly lower as compared to EphB3-EFNB2
binding values. EphB4 bound EFNB3 poorly as indicated bythe low M.F.I. values. Non-biotinylated EphB3 significantly
blocked binding of EphB4 to EFNB2. Although EphB4 binding
to EFNB3 was low, non-biotinylated EphB3 appeared to further
reduce EphB4 binding. Together these data suggest that both
Eph receptors bind to an overlapping domain of EFN and that
EphB3 has a stronger binding affinity than EphB4. Addition-
ally, subtle changes in the Eph binding domain of EFNB3 are
suggested as the binding of EphB3 was reduced as compared to
EphB3-EFNB2 binding and the binding of EphB4 was almost
undetectable.
Function of ephrin ligands as henipavirus receptors
To assess and compare each ephrin ligand and its ability to
support infection by HeVand NiV, all ephrin ligand transfections
Fig. 2. Amino acid sequence alignment of EFNB3 from different species. Species and amino acid number are listed on the left and right, respectively. Dots represent
identical amino acids. The transmembrane domain is indicated by boxed borders, cysteine residues are shaded in gray, and putative glycosylation sites are underlined.
GenBank accession numbers: horse EFNB3:EF682146; pig EFNB3:EF682147; cat EFNB3:EF682144; dog EFNB3:EF682145; P. alecto EFNB3:EF682148;
P. vamypyrus EFNB3:EF682149; mouse EFNB3:NM_007911.
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described in Materials and methods. All cells were fixed 20 h
post-infection and infected cells were visualized using immuno-
fluorescence assays as described in Materials and methods. The
ability of EFNB2 molecules from different species to support
infection by HeV or NiV are shown in Fig. 6. There did not
appear to be differences of species-specific EFNB2molecules in
their ability to support HeVinfection. All EFNB2molecules also
functioned similarly as viral receptors for NiV. Interestingly,
when comparing HeV and NiV infection in EFNB2 transfected
cells, the progression of the cytopathic effects (CPE) in NiV-
infected cells was further advanced as evidenced by the
increased number of rounded cells suggesting that HeV had a
slightly slower kinetics of infection. Previous studies have
suggested that HeV G appears to have a lower affinity for
EFNB2 than NiV G (Bossart et al., 2007) and the slower kineticsof HeV infection was consistent with a lower receptor affinity.
However, in the context of live virus infection, other viral
glycoproteins may have influenced the kinetics of virus
replication. Shown in Fig. 7 are the expression of EFNB3
molecules from different species and their ability to support HeV
or NiV infection. EFNB3 molecules from all species functioned
similarly for both HeV and NiV as demonstrated by the almost
equivalent amounts of HeV- and NiV-infected cells in all panels.
Interestingly, when comparing all infections, (Figs. 6 and 7), it
appears that only HeV in EFNB2 transfected cells had a slower
progression of CPE, all other infections seemed to progress
similarly. Analogous experiments using 100-fold less virus were
conducted and although the number of infected cells was
significantly decreased, infection kinetics and receptor function
closely paralleled results shown in Figs. 6 and 7 (data not
shown).
Fig. 3. Expression of species-specific EFNB2 molecules. HeLa-USU cells were grown to 80% confluence in 24 well plates and transfected with various EFNB2
constructs. Cells were probed with ephrin receptor EphB3 (His-epitope tagged) followed by a mouse anti-His FITC conjugate. A: vector control, B: human, C: horse,
D: pig, E: cat, F: dog, G: P. alecto, H: P. vampyrus, I: mouse.
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soluble receptor molecules
Previously we have demonstrated that soluble EFNB2 could
block HeV and NiV infection in Vero cells and EFNB2 trans-
fected cells at concentrations as low as 10 μg/ml (Bonaparte
et al., 2005). In the current studies we tested soluble receptors as
inhibitors of HeV and NiV infection in EFNB2 and EFNB3
transfected cells. Percent inhibitions were calculated as
described in Materials and methods and results are shown in
Table 3. EFNB3-mediated infections were completely blocked
by soluble EFNB2 for both viruses, strongly suggesting HeVand
NiV bind EFNB2 and EFNB3molecules through an overlapping
receptor binding domain. Although effective, soluble EFNB2
was less efficient at inhibiting NiV infection in EFNB2 trans-
fected cells even though there was two fold less virus as
compared to HeV. These data provide further evidence that NiV
G may have increased affinity for EFNB2 as compared to HeV.
When soluble EFNB3was used as a competitive inhibitor, it was
less effective against both viruses regardless of the species
(Table 3). When used at 10 μg/ml, no effect was seen (data not
shown). When increased to 25 μg/ml, EFNB3-mediated
infections were significantly inhibited and EFNB2-mediated
infections were only partially blocked. As both receptors appearto bind to the same domain of G it would seem likely that soluble
EFNB3 had a reduced affinity for HeVand NiVas compared to
EFNB2 and could not adequately compete for G binding. A
difference in affinity would be consistent with soluble EFNB2
completely blocking EFNB3-mediated infections (Table 3).
Soluble EFNB3 was more effective blocking EFNB2-mediated
HeV infection as compared to EFNB2-mediated NiV infection,
further suggesting that NiV has an increased affinity for EFNB2
as compared to HeV.
Functional mapping of the G receptor binding domain using
antibodies
Recently, m101 (Zhu et al., 2006) and m102.4 (Zhu et al., in
press), two recombinant human mAb, were identified whose
epitopes overlap with the EFNB2 binding domain of the
henipavirus G glycoproteins. Both antibodies can neutralize
HeVand NiV, although m101 is more effective against HeV (Zhu
et al., 2006) whereas m102.4 can potently neutralize both viruses
with somewhat higher potency for NiV (Zhu et al., in press). To
further evaluate the overlapping EFNB2 and EFNB3 binding
domain of G and to determine if the differential neutralization
profiles of m101 and m102.4 correlated with differential inhi-
bition of EFNB2 and/or EFNB3-mediated infection, we evaluated
Fig. 4. Expression of species-specific EFNB3 molecules. HeLa-USU cells were grown to 80% confluence in 24 well plates and transfected with various EFNB3
constructs. Cells were probed with ephrin receptor EphB3 (His-epitope tagged) followed by a mouse anti-His FITC conjugate. A: vector control, B: human, C: horse,
D: pig, E: cat, F: dog, G: P. alecto, H: P. vampyrus, I: mouse.
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infections. Percent inhibitions were calculated as described in
Materials and methods and results are shown in Table 3. Human
mAb m101 inhibited both EFNB2- and EFNB3-mediated HeV
infections in all species. NiV was significantly less susceptible to
inhibition by m101 and although low, inhibition levels wereFig. 5. Binding of EphB3 and EphB4 to recombinant EFN. Biotinylated EphB3/Fc (p
multiplexed microsphere assay as detailed in Materials and methods. Median fluoresc
EFNB2 (white bars) and EFNB3 (black bars). Binding was measured in the absence
assays were done in duplicate and the mean M.F.I. is shown. Error bars represent thsimilar in all species for both receptors. Together these data
demonstrate that the levels of m101 inhibition were dependent on
the virus used but not the specific EFN and suggest that m101
bound an overlapping EFNB2 and EFNB3 binding domain of the
attachment glycoprotein. Human mAb m102.4 was able to
potently block EFNB2-mediated infections in all species for bothanel A) or biotinylated EphB4 (panel B) were assayed for EFN binding using a
ence intensities (M.F.I.) are shown on the y-axis for each microsphere population;
(0) or presence of non-biotinylated Eph receptors as indicated on the x-axis. All
e range of M.F.I.
Fig. 6. HeVandNiVinfection of EFNB2-transfectedHeLa-USUcells.HeLa-USUcellswere grown to 80%confluence in 24well plates and transfectedwith various EFNB2
constructs. Transfected cells were infected with either HeVor NiV as described in Materials and methods. All infections were incubated for 20 h fixed in methanol and
immunofluorescently stained for P protein prior to digital microscopy. A: vector control, B: human, C: horse, D: pig, E: cat, F: dog, G: P. alecto, H: P. vampyrus, I: mouse.
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Fig. 7. HeVandNiVinfection of EFNB3-transfectedHeLa-USUcells.HeLa-USUcellswere grown to 80%confluence in 24well plates and transfectedwith variousEFNB3
constructs. Transfected cells were infected with either HeVor NiV as described in Materials and methods. All infections were incubated for 20 h fixed in methanol and
immunofluorescently stained for P protein prior to digital microscopy. A: vector control, B: human, C: horse, D: pig, E: cat, F: dog, G: P. alecto, H: P. vampyrus, I: mouse.
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Table 3
Percent inhibition a of HeV and NiV infection by molecules that target the henipavirus attachment glycoprotein
Inhibitor Ligand Virus Human Horse Pig Cat Dog P. alecto P. vampyrus Mouse
Soluble EFNB2 (10 μg/ml) EFNB2 HeV 99.8 98.5 99.3 98.3 99.3 99.3 99.5 99.3
NiV 87.3 84.6 90.9 88.6 91.8 90.5 90.9 89.1
EFNB3 HeV 100 100 100 100 100 100 100 100
NiV 100 100 100 100 100 100 100 100
Soluble EFNB3 (25 μg/ml) EFNB2 HeV 61.9 62.0 69.3 64.0 67.7 66.1 63.0 62.8
NiV 22.7 24.5 31.8 35.6 32.7 32.8 27.8 29.6
EFNB3 HeV 89.5 88.5 88.4 88.8 88.6 89.2 88.2 89.9
NiV 88.2 81.2 80.7 81.5 85.4 89.4 84.4 87.1
m101 (10 μg/ml) EFNB2 HeV 74.3 79.9 86.0 87.0 76.9 82.4 84.0 88.0
NiV 8.1 3.9 17.4 13.9 17.8 14.0 22.1 17.0
EFNB3 HeV 99.6 99.1 99.1 98.6 99.4 99.6 99.1 99.1
NiV 23.2 19.0 16.6 16.1 19.1 23.1 23.2 23.0
m101 (40 μg/ml) EFNB2 HeV 99.5 99.6 84.0 82.0 79.7 87.3 85.2 88.5
NiV 9.4 25.0 24.1 16.1 23.0 26.3 23.2 20.4
EFNB3 HeV 99.4 99.1 99.3 99.6 99.1 99.6 99.3 99.6
NiV 29.7 30.2 25.3 32.2 25.4 27.2 28.1 26.7
m102.4 (10 μg/ml) EFNB2 HeV 90.3 89.4 90.8 92.9 91.0 86.9 92.0 88.9
NiV 73.6 75.0 74.3 73.6 75.7 71.4 73.6 74.3
EFNB3 HeV 98.7 98.4 94.7 94.2 94.7 98.2 94.9 93.8
NiV 99.7 99.4 99.7 99.7 99.7 99.4 99.7 99.7
m102.4 (50 μg/ml) EFNB2 HeV 92.5 92.4 93.1 92.9 94.1 94.0 94.0 93.3
NiV 80.0 81.4 78.6 79.3 83.6 81.4 82.9 81.4
EFNB3 HeV 99.7 99.6 99.1 99.3 99.5 99.7 99.6 99.5
NiV 99.4 99.4 99.4 99.4 99.4 99.7 99.7 99.7
a Percent inhibitions were calculated as detailed in Materials and methods.
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NiV. Human mAb m102.4 was also able to inhibit EFNB3-
mediated infections for both viruses in all species and inhibition
was increased (N99%) as compared to inhibition of EFNB2-
mediated infection. Together these data suggest that like m101,
m102.4 blocked infection of HeV and NiV by binding to an
overlapping EFNB2 and EFNB3 binding domain of the attach-
ment glycoprotein. Importantly, for m102.4, HeV and NiV
neutralization was achieved in the context of all EFN receptors
from all tested species demonstrating its potential as a potent
cross-reactive therapeutic for NiVand HeV infections in animals
and humans.Fig. 8. Competition of Eph binding by sG. Biotinylated EphB3/Fc (panel A) or bio
microsphere assay as detailed in Materials and methods. Median fluorescence intens
(white bars) and EFNB3 (black bars). Binding was measured in the absence (0) or pre
mean M.F.I. is shown. Error bars represent the range of M.F.I.EFN receptor binding domains overlap with the henipavirus G
binding domain
Finally, we sought to determine if the Eph binding domain of
EFNB2 and EFNB3 were involved in G glycoprotein binding.
Using the multiplexed EFN-Eph microsphere assay as
described in Materials and methods, we assessed whether
soluble versions of the henipavirus attachment glycoproteins
(sG) could inhibit Eph-EFN binding and results are shown in
Fig. 8. Binding of EphB3 to EFNB2 was significantly inhibited
by sG-HeV and sG-NiV (Fig. 8A). EphB3 binding to EFNB3
was also significantly reduced, although inhibition by sG-HeVtinylated EphB4 (panel B) were assayed for EFN binding using a multiplexed
ities (M.F.I.) are shown on the y-axis for each microsphere population; EFNB2
sence of sG as indicated on the x-axis. All assays were done in duplicate and the
Fig. 9. Percent Inhibition of HeVand NiV infection by Eph receptors. HeLa-USU cells were grown to 80% confluence in 24 well plates and transfected with human
EFNB2 and EFNB3 constructs. Transfected cells were incubated in the presence or absence of EphB3 or EphB4 for 30 min and subsequently infected with either HeV
or NiV as described in Materials and methods. HeV and NiV infected cells were immunofluorescently labeled for P protein and counted in all groups. Percent
inhibitions were calculated as detailed in Materials and methods. Eph inhibition assays were done in duplicate and the average percent inhibition of HeV (white bars) or
NiV (black bars) is shown. Error bars represent the range of percent inhibition. Inhibition of EFNB2 and EFNB3-mediated infections by EphB3 is shown in Panel A;
inhibition of EFNB2-mediated infections by EphB4 is shown in Panel B.
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cantly reduced by sG (Fig. 8B) and here, inhibition by sG-NiV
was less efficient. As demonstrated previously, EphB4 bound
EFNB3 poorly, nonetheless both sG molecules further reduced
EphB4 binding. Together these data suggest that the Eph bind-
ing domains of EFNB2 and EFNB3 overlap with the henipa-
virus attachment protein binding domain. Furthermore, both
EphB3 and EphB4 binding were inhibited by sG, which pro-
vides further evidence that EphB3 and EphB4 bind through an
overlapping binding domain of EFN. Next we assessed Eph
receptors for their ability to block HeV and NiV infections in
EFN transfected cells. Because binding of EphB4 to EFNB3
was not detected by immunofluorescence and was very low
using recombinant EFNB3, EphB4 was only assayed for its
ability to block EFNB2-mediated henipavirus infections. Due to
the Eph concentrations employed (50 μg/ml) and reagent
limitations, we were only able to use human EFN transfected
cells in henipavirus Eph inhibition assays and results are shown
in Fig. 9. Percent inhibitions were calculated as described in
Materials and methods. EphB3 blocked approximately 75% of
EFNB2- and EFNB3-mediated infections for both HeVand NiV
(Fig. 9A). EphB4 blocked approximately 70% of EFNB2-med-
iated infections for HeV and approximately 40% of EFNB2-
mediated infections for NiV (Fig. 9B). These data provide
further evidence that the overlapping EphB3/EphB4 binding
domain of EFNB2 and EFNB3 overlaps with the domain that
binds the henipavirus G glycoproteins. Importantly, EphB3
blocked HeV and NiV infections regardless of the EFN used
suggesting it may potentially represent a new avenue for thera-
peutic antiviral drug development.
Discussion
HeV and NiV can use at least two different receptors for
infection, and it was speculated that differences could exist
between the receptors from one animal species to another
influencing the pathogenic process. For these reasons we clonedand characterized both of these receptors from a host of
naturally or experimentally susceptible species and examined
their function as henipavirus receptors. We found that there was
almost no variation in receptor function, regardless of species,
suggesting that host receptor molecules do not play a major role
in differential infection. We specifically included mouse EFN
molecules in the current study as these animals are highly
resistant to systemic infection with HeV and NiV. Recently, it
was reported that two rodent cell lines known to express EFNB2
were resistant to NiV infection (Yoneda et al., 2006). Our results
demonstrate that mouse EFN molecules are highly functional
henipavirus receptors when expressed in HeLa-USU cells, sug-
gesting that resistance to HeVand NiV infection in mice is most
likely due to a post-entry block in virus replication. It is possible
that receptor expression and distribution vary in different
species, although given their high level of conservation and
essential functions, we believe this to be unlikely. Nonetheless,
we are currently investigating this possibility. We also demon-
strated that HeV and NiV used EFNB2 and EFNB3 similarly
indicating that the differences in disease were unlikely to be due
to selective use of receptors by either virus. HeV appeared to
have a slightly slower kinetics of infection in EFNB2 trans-
fected cells as compared to NiV regardless of the source species.
These observed differences are consistent with previous data
which demonstrated that NiV G had a slightly increased asso-
ciation constant (ka) for EFNB2 (Bossart et al., 2007). However,
HeV- and NiV-specific proteins other than the attachment
glycoprotein, including the fusion glycoprotein or those in-
volved with the replication machinery, could also lead to the
observed replication differences as cell type-specific differences
in HeV and NiV replication have been observed previously
(Crameri, G., unpublished observation). EFNB3-mediated
infections were similar for both HeV and NiV in all species
with CPE similar to EFNB2-mediated NiV infections. Previous
work has demonstrated that NiV G has an increased affinity
for EFNB2 as compared to EFNB3 (Negrete et al., 2006). The
difference in affinity was not attributed to differences in the
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constants (kd). Importantly, this “faster off rate” of EFNB3 does
not appear to influence infectivity in vitro as there was no
difference in the kinetics of EFNB2- and EFNB3-mediated NiV
infections. Analysis of all infectivity data suggests that the
previously described association constants of HeV and NiV G
for their receptors do correlate with live virus infection.
Recent data using biochemical and pseudovirus assays have
suggested that HeV and NiV G bind EFNB2 and EFNB3
molecules through an overlapping receptor binding domain
(Bishop et al., 2007; Negrete et al., 2006). To further examine
this possibility using live HeVand NiV we tested two classes of
entry inhibitors, soluble EFN molecules and G-specific human
mAb known to interfere with EFNB2 binding. Soluble EFNB2
blocked EFNB2- and EFNB3-mediated HeVand NiV infections
in all species indeed establishing that both receptor molecules
bind to the same or overlapping domain of G. Soluble EFNB3
could neutralize EFNB3-mediated infections but only partially
neutralized EFNB2-mediated infections. We hypothesize that
this is not due to where EFNB3 binds on G but due to a lower
affinity not sufficient for EFNB2 competition. The previously
described decreased disassociation constant would be consistent
with these data. The hmAb m101 and m102.4 blocked infection
of HeV and NiV regardless of the receptor used, indicating
independently that the receptor binding domain for both EFNB2
and EFNB3 molecules overlapped with the epitopes of G that
bind m101 and m102.4. The differential neutralization of HeV
and NiV by m101 most likely represents minor amino acid
differences between the attachment proteins that influence
m101 binding. We also found that m102.4 was slightly more
effective against HeV at the high antibody concentrations used
in these studies. Interestingly, we have previously observed that
at lower concentrations this antibody was more active against
NiV compared to HeV resulting correspondingly to lower IC50
although at the highest concentration it neutralized HeV
better than NiV (Zhu et al., in press). The mechanisms of
such concentration-dependent differential neutralization are
complex and are currently being investigated. Regardless, the
neutralization by m102.4 was very potent and cross-reactive,
suggesting potential use of this antibody as a therapeutic agent
for henipavirus infection (Zhu et al., in press).
Finally, we evaluated EFN receptor binding domains to
determine if they played a role in henipavirus binding and
infection. Due to sensitivity problems and limited reagents, we
established a new microsphere assay capable of detecting EFN-
Eph interactions which was particularly useful for EFN-EphB4
binding studies and Eph competition studies. We were able to
demonstrate that EphB3 and EphB4 most likely bound an
overlapping binding domain of EFN and that sG could block
Eph binding. Consequently, we evaluated Eph receptors for
their ability to inhibit henipavirus infection and found that
EphB3 significantly inhibited henipavirus infections regardless
of receptor use whereas EphB4 bound and inhibited EFNB2-
dependent infections. EphB4 inhibited HeV better than NiV in
EFNB2-expressing cells and we speculate that this may be due
to relative differences in EFNB2 affinity as compared to EphB4.
Together the Eph binding and inhibition data suggested anoverlapping Eph binding domain within EFNB2 and EFNB3
which overlapped with the henipavirus G glycoprotein binding
domain. It will be interesting to determine if binding of the
henipavirus G glycoprotein mimics EphB3 and EphB4 binding
and leads to signaling through the ephrin ligands. Ephrin
ligands and their receptors participate in bi-directional signaling
events and research suggests that this bi-directional signaling is
crucial in controlling vascular homeostasis (Augustin and Reiss,
2003). If the henipavirus G glycoproteins stimulate one-way
signaling via the ephrin ligands, it may promote improper
endothelial cell migration leading to imbalance in the vascular
system, possibly explaining the general vasculitis seen in HeV
and NiV infected individuals.
Materials and methods
Tissue samples and total RNA isolation
Fresh kidney and liver tissue samples were obtained from
horse, pig, cat, dog, P. alecto, P. vampyrus and mouse and were
stored in RNAlater (Ambion Inc. Austin, TX, USA) at −80 °C.
RNA was extracted using RNeasy Mini kit (Qiagen Pty. Ltd.,
Clifton Hill, VIC, Australia) following the manufacturer's
protocol. Tissue homogenization and disruption was as described
previously (Tachedjian et al., 2006). Briefly, 80 mg of tissue
stored in RNALater was added to tubes containing 1.8 ml RLT
lysis buffer (RNeasy) containing 18 μl β-mercaptoethanol and
15×2.3 mm diethyl pyrocarbonate (Sigma-Aldrich, St. Louis,
MO, USA) treated stainless steel balls (BioSpec Products Inc.,
Bartlesville, OK, USA). Samples were then homogenized for 3
cycles of 30 s using a Mini-Bead Beater 8 (Biospec Products
Inc.), centrifuged to pellet cell debris and the supernatant
transferred to a new tube. All samples were then processed as
per the manufacturer's instructions supplied with the RNeasy kit.
RNAwas either used immediately for cDNA synthesis or stored
at −80 °C for future use.
Synthesis of cDNA
Procedures previously described (Tachedjian et al., 2006)
were used with the following modifications. Between 1.5 and
2.0 μg of total RNA was denatured for 10 min at 65 °C then
added to a 20 μl reaction mixture containing 1X reverse
transcription (RT) buffer (Qiagen Pty. Ltd.), 10 units RNasin
(Promega, Madison, WI, USA), 0.5 mM dNTPs (Qiagen Pty.
Ltd.), 4 uM random hexamers (Promega), 1 uM oligo dT12–18
(Qiagen Pty, Ltd.) and 4 units Omniscript-RT (Qiagen Pty.
Ltd.). First strand synthesis was performed for 5 min at room
temperature then 2 h at 37 °C. Reactions were immediately
stored at −20 °C.
5′ and 3′ RACE
Alignments of known EFNB2 and EFNB3 DNA sequences
were conducted using CloneManager Professional Suite version
8 (Scientific and Educational Software, Cary, NC, USA) and
highly conserved regions were identified for both EFNB2 and
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molecules (Table 1) and used in PCR to generate a 747 base pair
(bp) internal fragment of EFNB2 (horse, cat, P. alecto and
P. vampyrus) and a 900 bp internal fragment for EFNB3 (horse,
P. alecto and P. vampyrus). PCR products were sequenced and
primers were designed for 5′ and 3′ RACE (Table 1). 5′ and 3′
RACE was performed using the Ambion FirstChoice™ RLM-
RACE kit (Applied Biosystems, Scoresby, VIC, Australia) with
modifications for cDNA synthesis and PCR amplifications as
previously described (Tachedjian et al., 2006).
Cloning of full length EFNB2 and EFNB3
For horse, cat, P. alecto and P. vampyrus EFNB2 molecules
and for horse, P. alecto and P. vampyrus EFNB3 molecules,
consensus primers were designed based on RACE sequences. For
pig, dog and mouse EFNB2 molecules and cat, pig, dog and
mouse EFNB3 molecules, primers were designed based on pre-
viously published sequences (GenBank accession numbers: pig
EFNB2:AJ667124 and DB784906; dog EFNB2:XM849457;
mouse EFNB2:NM_010111; cat EFNB3:6308350020,
AANG01159385 and AANG01159384; pig EFNB3:AC127472;
dog EFNB3:XM844752; mouse EFNB3:NM_007911). Consen-
sus primers were used for subcloning of human EFNB2 and
EFNB3 molecules. All cloning primers are listed in Table 1. For
each species except human, cDNAwas synthesized as described
above and 1.5 μl of cDNAwas used as template for PCR in a 25μl
reaction. For human EFNB2 and EFNB3 molecules 1 μl of
previously obtained expression plasmids (Bonaparte et al., 2005)
were used as PCR templates. All PCR reactions were performed
using Qiagen's Proofstart DNA polymerase with Q solution
(Qiagen Pty. Ltd.) with the following settings: 94 °C for 5 min
initially and then 94 °C for 1 min, 60 °C (EFNB2) or 61 °C
(EFNB3) for 1 min, 72 °C for 1 min 15 s; 45 cycles, 72 °C for
10 min. All primers generated PCR products with a 5′ Kozak
sequence (CCACC), 3′ stop codon and flanking 5′ and 3′ SalI
sites. PCR products were gel purified (Qiagen Pty. Ltd.) and
cloned into the TOPO vector (Invitrogen Australia Pty. Ltd.,
MountWaverley, VIC,Australia) and subsequently subcloned into
the pcDNA3.1 myc-his expression vector (Invitrogen Australia
Pty. Ltd.). All clones were verified by PCR, restriction digest and
2-fold DNA sequencing. For mouse EFNB2, a mutation was
introduced in the first codon during subcloning (atg to ttg). This
mutation gives rise to a truncatedmouseEFNB2 that ismissing the
first two amino acids.
Transient expression of EFN molecules
HeLa-USU cells (Bonaparte et al., 2005; Bossart et al., 2005)
were seeded in 24 well plates in Dulbecco's modified Eagle's
medium (DMEM) (Invitrogen Australia Pty. Ltd.) containing
10% fetal calf serum (FCS) (Invitrogen Australia Pty. Ltd.) and
2 mM glutamax (Invitrogen Australia Pty. Ltd.) (DMEM-10) to
achieve 215,000 cells per well. HeLa-USU cells were
transfected with either a plasmid encoding EFNB2, EFNB3
or vector alone using Fugene transfection reagent (Roche,
Indianapolis, IN, USA) per the manufacturer's instructions.DNA-Fugene mixtures were added to cells and incubated
overnight at 37 °C in a humidified 5% CO2 atmosphere.
Medium was removed and cells were washed once with Ca++
and Mg++ free PBS (PBSA). For HeV and NiV infections,
200 μl of DMEM containing 10% FCS and 2 mM glutamax was
added per well. For immunofluorescence, 200 μl of DMEM
containing 1% bovine serum albumin (BSA) and 2 mM gluta-
max was added per well.
Immunofluorescence assays for EFN molecules
All assays were done using live transfected cells. Cells were
incubated in DMEM containing 1% BSA and 2 mM glutamax
for 30 min at 37 °C in a humidified 5% CO2 atmosphere. Cells
were washed three times with PBS containing 0.05% Tween-20
(PBST). 800 ng recombinant mouse EphB3/Fc (Bio-Scientific
Pty. Ltd., Gymea, NSW, Australia) or 400 ng recombinant
human EphB4 (Bio-Scientific Pty. Ltd.) were added to each
well in 200 μl DMEM containing 1% BSA and 2 mM glutamax
and incubated for 30 min at 37 °C in a humidified 5% CO2
atmosphere. Cells were washed three times with PBST. 200 μl
of fluorescein isothiocyanate (FITC) conjugated mouse anti-His
antibody (Milenyi Biotec Australia Pty. Ltd, NSW, Australia)
diluted 1:100 in DMEM containing 1% BSA and 2 mM gluta-
max was added per well and incubated in the dark for 30 min at
37 °C in a humidified 5% CO2 atmosphere. Cells were washed
three times with PBST and 0.5 ml PBSA was added per well.
FITC immunofluorescence was visualized using an Olympus
IX71 inverted microscope (Olympus Australia, Mt. Waverley,
VIC, Australia) coupled to an Olympus DP70 high resolution
color camera and all images were acquired at an original mag-
nification of 20×.
Eph-EFN binding and competition assays
10 μg of recombinant mouse EFNB2/Fc or recombinant
human EFNB3/Fc (Bio-Scientific Pty. Ltd.) were coupled to
5×105 carboxylated (COOH) microspheres (Fisher Biotec.,
Wembley, WA, Australia), bead sets #42 and #46, respectively,
as described previously (Bossart et al., 2007). 10 μg recombinant
mouse EphB3/Fc (Bio-Scientific Pty. Ltd) or 5 μg recombinant
human EphB4 (Bio-Scientific Pty. Ltd.) were biotinylated using
a Lightning-Link™ Biotin conjugation kit (Innova Biosciences
Ltd., Babraham, Cambridge, UK) following the manufacturer's
protocol. For all multiplexed assays, multiScreen-BV 1.2 μm
hydrophilic, low protein binding, 96-well filter plates (Millipore
Australia Pty Ltd, North Ryde, NSW, Australia) were pre-wet
with PBSA. EFN-coupled microspheres were vortexed and
sonicated for 1 min. PBSA was removed from pre-wet 96-well
filter plates using a vacuum manifold and 100 μl of PBSA
containing 1500 microspheres of each bead set was added per
well. PBSAwas removed using a vacuummanifold and 100 μl of
biotinylated EphB3/Fc (1:500) or biotinylated EphB4 (1:500)
was added per well and incubated for 30 min at room tem-
perature with shaking in the dark. Liquid was removed using the
vacuum manifold and 100 μl of streptavidin–phycoerythrin
(1:1000) (Qiagen Pty. Ltd.) was added per well and incubated for
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biotinylated EphB3/Fc or EphB4 (50 μg/ml) or 50 μl sG-HeVor
sG-NiV (Bossart et al., 2007) (10 μg/ml) were added prior to the
addition of biotinylated Eph receptors and incubated for 30 min
as described above. Liquid was removed using the vacuum
manifold and biotinylated Eph receptors and streptavidin–
phycoerythrin were added as described above. All samples were
assayed for median fluorescence intensities (M.F.I.) on the Bio-
Plex Protein Array System as previously described (Bossart
et al., 2007).
HeV and NiV infection and immunofluorescence assay
All live virus experiments were conducted under strict bio-
containment procedures in a biological safety level-4 (BSL4)
laboratory. To each well of transfected HeLa-USU monolayers,
1.6×106 TCID50 HeV or NiV was added. All infections were
done in DMEM-10 in a total volume of 400 μl per well and were
incubated overnight at 37 °C in a humidified 5% CO2 atmo-
sphere. The culture medium was discarded the next day, and
plates immersed in ice-cold absolute methanol for 20 min prior
to air-drying outside the BSL4 laboratory. Infected cells were
immunofluorescently labeled with anti-P antiserum and viewed
as previously described (Bonaparte et al., 2005).
HeV and NiV inhibition assays
The amount of virus chosen for all inhibition assays was
based on what has been used previously, 8000 TCID50
(Bonaparte et al., 2005). As HeV infection progressed more
slowly in transfected cells than NiV, we chose to use two fold
more virus for HeV as compared to NiV. For inhibition by
soluble receptors, 40 μg recombinant mouse EFNB2/Fc (Bio-
Scientific Pty. Ltd.) or 100 μg recombinant human EFNB3/Fc
(Bio-Scientific Pty. Ltd.) were mixed with 1.6×105 TCID50
HeVor 0.8×105 TCID50 NiV in 4 ml DMEM-10. For inhibition
by antibodies, 40 μg or 160 μg m101 (Zhu et al., 2006) or 40 μg
or 200 μg affinity purified m102.4 (Zhu et al., in press) were
mixed with 1.6×105 TCID50 HeV or 0.8×10
5 TCID50 NiV in
4 ml DMEM-10. All virus–inhibitor mixtures were incubated
for 30 min at 37 °C, media from transfected HeLa-USU cells
was removed and 400 μl of virus–inhibitor mixtures were added
per well and cells were incubated overnight at 37 °C in a
humidified 5% CO2 atmosphere. For inhibition by Eph
receptors, 20 μg recombinant mouse EphB3/Fc (Bio-Scientific
Pty. Ltd.) or 20 μg recombinant human EphB4 (Bio-Scientific
Pty. Ltd.) were added to transfected HeLa-USU monolayers in
200 μl (100 μg/ml) and incubated for 30 min at 37 °C. 200 μl
DMEM-10 containing 3.2×105 TCID50 HeV or 1.6×10
5
TCID50 NiV was added to each well. Eph–virus mixtures
were incubated on cell monolayers for 30 min at 37 °C, washed
once with PBSA and further incubated in 400 μl DMEM-10
overnight at 37 °C in a humidified 5% CO2 atmosphere. Cells
were fixed, immunofluorescently labeled with anti-P antiserum
and viewed as previously described. Percent inhibitions were
calculated for each species using the following equation:
100×(1−number of infected cells in species-specific inhibi-tor-treated well / number of infected cells in species-specific
untreated well).
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